<DOC>
	<DOCNO>NCT00439725</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , event-driven , superiority study efficacy . Patients confirm symptomatic DVT ( deep vein thrombosis ) PE ( pulmonary embolism ) complete 6 12 month treatment rivaroxaban VKA ( vitamin K antagonist ) eligible trial ( Einstein-Extension study ) .</brief_summary>
	<brief_title>Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism . The Einstein-Extension Study</brief_title>
	<detailed_description>Within US 'Johnson &amp; Johnson Pharmaceutical Research &amp; Development , L.L.C . ' sponsor . The treatment period follow observational period 30 day start day last intake study medication , regardless actual duration study drug administration . Participants complete treatment period also enter observational period . It also possible participant enter observational period , e.g . due withdrawal consent termination study participation .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Patients confirm symptomatic PE DVT treat 6 12 month VKA rivaroxaban Legal low age limitation ( country specific ) Indication VKA DVT and/or PE Patients anticoagulant treatment index PE DVT continue Childbearing potential without proper contraceptive measure , pregnancy breast feeding . Proper contraceptive measure define method contraception failure rate &lt; 1 % course study ( include observational period ) . These method contraception accord note guidance nonclinical safety study conduct human trial pharmaceutical ( CPMP [ Committee Proprietary Medicinal Products ] /ICH [ International Conference Harmonization ] /286/95 , modification ) include consistent correct use hormone contain implant injectables , combine oral contraceptive , hormone contain intrauterine device , surgical sterilization , sexual abstinence vasectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>